Show simple item record

dc.contributor.authorMeluzinova, Eva
dc.contributor.authorO'Neill, Gilmore
dc.contributor.authorYang, Minhua
dc.contributor.authorERAKSOY, Mefküre
dc.contributor.authorRektor, Ivan
dc.contributor.authorKappos, Ludwig
dc.contributor.authorGold, Ralf
dc.contributor.authorMiller, David
dc.contributor.authorMacManus, David G.
dc.contributor.authorHavrdova, Eva
dc.contributor.authorLimmroth, Volker
dc.contributor.authorPolman, Chris
dc.contributor.authorSchmierer, Klaus
dc.contributor.authorYousry, Tarek
dc.date.accessioned2022-02-18T09:24:33Z
dc.date.available2022-02-18T09:24:33Z
dc.identifier.citationKappos L., Gold R., Miller D., MacManus D. G. , Havrdova E., Limmroth V., Polman C., Schmierer K., Yousry T., Yang M., et al., "Safety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis", 59th Annual Meeting of the American-Academy-of-Neurology, Massachusetts, Amerika Birleşik Devletleri, 28 Nisan - 05 Mayıs 2007, cilt.68
dc.identifier.othervv_1032021
dc.identifier.otherav_38520b34-fbb8-43e4-b1bc-c35d59734d81
dc.identifier.urihttp://hdl.handle.net/20.500.12627/177152
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectNöroloji
dc.subjectNeurology
dc.subjectNeurology (clinical)
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectKLİNİK NEUROLOJİ
dc.subjectTıp
dc.titleSafety and tolerability results of a phase 2b extension study of the novel oral fumarate BG00012 for the treatment of relapsing-remitting multiple sclerosis
dc.typeBildiri
dc.contributor.department, ,
dc.identifier.volume68
dc.contributor.firstauthorID3374801


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record